Table 1.
Clinicopathologic findings at diagnosis of the PCa patients used in RNA sequencing (n = 84).
Figure 1.
Relative ARLTS1 RNA expression from PCa patients and healthy controls.
Relative ARLTS1 RNA expression was determined by RNA sequencing analysis. Columns represent means of individuals; bars represent SD.
Figure 2.
Schematic diagram showing the genomic locations of eSNPs gathered by eQTL analysis in PCa patients.
The gene symbols are as follows: CYSLTR2 (cysteinyl leukotriene receptor 2), FNCD3A (fibronectin type III domain containing 3A), MLNR (motilin receptor), CDADC1 (cytidine and dCMP deaminase domain containing 1), CAB39L (calcium binding protein 39-like), SETDB2 (SET domain, bifurcated 2/CLLD8), PHF11 (PHD finger protein 11/NY-REN-34 antigen), RCBTB1 (regulator of chromosome condensation [RCC1] and BTB [POZ] domain containing protein 1/CLLD7), ARLTS1 (/ARL11, ADP-ribosylation factor-like 11), EBPL (emopamil binding protein-like), KPNA3 (karyopherin alpha 3, importin alpha 4), SPRYD7 (SPRY domain containing 7/C13orf1, chromosome open reading frame 1), MIR3613 (microRNA 3613), TRIM13 (tripartite motif containing 13), KCNRG (potassium channel regulator), MIR-15A and MIR16-1 (microRNA genes 15a and 16-1) and DLEU2 (deleted in lymphocytic leukemia 2).
Table 2.
Chromosomal region 13q14 risk variants (eSNPs) associated with differential ARLTS1 expression.
Figure 3.
Correlation of the different genotype groups of eSNPs to ARLTS1 RNA expression levels.
A, rs2075610; B, rs7997737; C, rs1543513; D, rs9568232; E, rs9568354; F, rs1886014; G, rs7337547; H, rs7995192; I, rs9562905; J, rs2580189; K, rs2532975; L, rs1262781; M, rs1262774 and N, rs17074618.
Table 3.
ARLTS1 Co-expression signatures from tumor specimens and cell lines.